Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn's disease.

Crohn's disease (CD) is characterized by malfunction of immune-regulatory mechanisms with disturbed intestinal mucosal homeostasis and increased activation of mucosal immune cells, leading to abnormal secretion of numerous pro- and anti-inflammatory mediators. MCP2/CCL8 is produced by intestinal epithelial cells and macrophages, and is a critical regulator of mucosal inflammation. NLRC4 is expressed in phagocytes and intestinal epithelial cells and is involved in intestinal homeostasis and host defense. However, no study to date has assessed the circulating levels of NLRC4 and MCP2/CCL8 in patients with CD. The study was aimed to investigate the serum levels of MCP2/CCL8 and NLRC4 in patients with active CD. Sixty-nine patients with active CD and 60 healthy participants were included in the study. Serum levels of NLRC4 and MCP2/CCL8 were determined using an enzyme-linked immunosorbent assay. The median serum NLRC4 levels were lower in the patient group than in the controls (71.02 (range, 46.59-85.51) pg/mL vs. 99.43 (range 83.52-137.79) pg/mL) (P < 0.001). The median serum levels of MCP2/CCL8 were decreased in patients with CD (28.68 (range, 20.16-46.0) pg/mL) compared with the controls (59.96 (range, 40.22-105.59) pg/mL) (P < 0.001). Cut-off points of NLRC4 (<81 pg/mL) and MCP2/CCL8 (<40 pg/mL) showed high sensitivity and specificity for identifying active CD. In conclusion, this is the first study to examine circulating levels of MCP2/CCL8 and NLRC4 in patients with active CD. Our results suggest that serum NLRC4 and MCP2/CCL8 levels may be involved in the pathogenesis of CD and may have a protective effect on intestinal homeostasis and inflammation. Serum levels of MCP2/CCL8 and NLRC4 could be used as a diagnostic tool and therapeutic target for CD.

Introduction

Crohn’s disease (CD) is a chronic inflammatory condition characterized by transmural, remitting and relapsing, focal inflammation involving different sites of the gastrointestinal tract, from the mouth to the anus [1]. The epidemiology of the disorder, traditionally regarded as a condition of developed countries, is changing around the world at the beginning of the 21st century with the rapid increase in the incidence of newly industrialized countries in Asia, South America, and Africa [2]. Rapid changes in CD epidemiology have led to a global challenge for disease diagnosis, management, and prevention, as well as creating a significant socioeconomic burden for healthcare systems. Although the risk of development and progression of CD might be affected by environmental and nutritional factors, immunologic characteristics, impaired intestinal barrier function, and gut microbiota dysbiosis in genetically susceptible individuals, the exact etiopathogenesis remains unknown [3]. Abnormal expressions of pro- and anti-inflammatory molecules including cytokines, chemokines, inflammasomes, miRNAs, and neuropeptides in both innate and adaptive immune responses are the central driver of CD, suggesting that these molecules may be used as potential diagnostic and therapeutic targets for future genetic and immunologic research [4].

Chemokines are a large family of small proteins that play a significant role in mucosal homeostasis and inflammation. Chemokines are secreted by both resident mucosal cells and a wide range of infiltrating cells including T cells, macrophages, and neutrophils, which are present in CD lesions [5]. Chemokines can attract inflammatory cells into CD tissue lesions and regulate tissue-specific and immune cell selective trafficking and leukocyte retention at the site of inflammation, contributing to the tissue destructive processes in the development and progression of CD [6]. Chemokine (C-C motif) ligand 8 (CCL8), also known as monocyte chemoattractant protein 2 (MCP2), is a small cytokine belonging to the CC chemokine family, which is involved in the inflammatory response by attracting and activating many different immune cells including monocytes, T cells, natural killer cells, eosinophils, and basophils. Experimental studies have shown that MCP2/CCL8 is produced by intestinal epithelial cells and macrophages and is a critical regulator of mucosal inflammation [7]. However, circulating levels of MCP2/CCL8 have not been investigated in patients with CD.

Inflammasomes are cytosolic multiprotein complexes that detect and eliminate both pathogens and damage-associated molecular patterns in innate immunity [8]. Inflammasome activation can lead to pyroptosis, a unique form of cell death with characteristics of classic apoptosis (caspase activation) and necrosis (membrane permeabilization) [9]. The impairment of inflammasome activation may contribute to the pathogenesis of various conditions including cancer, autoimmune disorders, metabolic, and neurodegenerative diseases [10]. Recent studies have shown that inflammasome activity is essential for intestinal homeostasis and discrimination of harmful pathogens and commensals [11]. Inflammasomes consist of nucleotide-binding and oligomerization domain-like receptor family (NLR) proteins such as NLRP1, NLRP3, NLRP6, and NLR-caspase activation and recruitment domain-containing protein 4 (NLRC4). NLRC4, also known as interleukin (IL)-converting enzyme protease-activating factor, is expressed in phagocytes and intestinal epithelial cells and is involved in intestinal homeostasis and host defense, especially against enteric pathogens [12]. It was reported that the mutation of NLRC4 could cause a syndrome of enterocolitis and autoinflammation [13]. However, no study to date has assessed the circulating levels of NLRC4 in patients with CD.

The aim of the study was to investigate the serum levels of MCP2/CCL8 and NLRC4 in patients diagnosed as having active CD.

Material and methods

This study was conducted between July 2020 and January 2021 in the Departments of Internal Medicine and Gastroenterology of Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey. Sixty-nine patients with active CD and 60 healthy control participants were included in the study. CD was diagnosed in accordance with the criteria reported by the European Crohn´s and Colitis Organization (ECCO), based on anamnesis, physical examination, magnetic resonance imaging, as well as gastrointestinal tract endoscopic examinations including gastroscopy and colonoscopy with histopathologic evaluations [14]. Disease activity was determined using the CD Activity Index score (CDAI), and patients with a score of more than 200 points for a minimum of 2 weeks before randomization were defined as having active CD [15]. Participants with acute or chronic infections, malignancy, chronic inflammatory conditions, pregnant patients and those within 1 year postpartum, a history of concomitant autoimmune diseases, and also those in remission of CD were excluded from the study. The control group comprised healthy individuals with no known gastrointestinal disorders or history of chronic or autoimmune disease, as well as medication use. Clinical and demographic characteristics including age, sex, current medication, the sites of gastrointestinal involvement, Column L, Column M, and CD type were obtained from patients’ records. All research procedures were evaluated and accepted by the Research Ethics Committee of Kanuni Sultan Suleyman Training and Research Hospital and were conducted in agreement with the ethical standards specified in the Declaration of Helsinki. Written and verbal informed consent was obtained from all participants before they participated in the study.

Blood samples were drawn from the antecubital vein after a 12-hour fast and were centrifuged at 3000 rpm for 10 min to separate the serum. Serum samples for NLRC4 and MCP2/CCL8 were stored at -40°C until the analyses were completed. Complete blood count and serum C-reactive (CRP) levels were measured on the sampling day. Complete blood count including white blood cell count (WBC), red blood cell count (RBC), red blood cell distribution width (RDW), hemoglobin values, leukocytes subtypes, platelet counts, and mean platelet volume (MPV) were measured using a Mindray BC-6800 autoanalyzer (Mindray Electronics Co, Ltd, Shenzhen, China). The neutrophil-to-lymphocyte ratio (NLR) was calculated as a simple ratio of the absolute counts of neutrophils divided by absolute lymphocyte counts, and the platelet-to-lymphocyte ratio (PLR) were determined by dividing the platelet count by the lymphocyte count. Serum CRP levels were determined using an immunoturbidimetric method with an Olympus AU 400 biochemical autoanalyzer (Olympus Optical, Tokyo, Japan) and expressed as mg/L.

After thawing frozen serum samples, serum NLRC4 was determined using an enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer’s instructions (SinoGeneclon Biotech, HangZhou, China). The detection range of the NLRC4 assay was 7.5–1200 pg/mL, and the analytical sensitivity was 3.9 pg/mL. Serum MCP2/CCL8 levels were measured using ELISA kits based on the instruction manual (SinoGeneclon Biotech, HangZhou, China). The analytical sensitivity of the MCP2/CCL8 was 0.8 pg/mL, and the detection range was 3.3–200 pg/mL. The intra-assay coefficient of variation of NLRC4 and MCP2/CCL8 was <8%, and the inter-assay coefficient of variation was <10%.

Statistical analyses

All analyses were performed on the SPSS v21 software (SPSS Inc., Chicago, IL, USA). The Kolmogorov-Smirnov test was used to check normality of distribution. Data are given as mean ± standard deviation (SD) or median (1st quartile—3rd quartile) for continuous variables according to the normality of distribution and as frequency (percentage) for categorical variables. Normally distributed variables were analyzed using the independent samples t-test. Non-normally distributed variables were analyzed using the Mann-Whitney U test. Categorical variables were analyzed using Chi-square tests or Fisher’s exact test. Spearman correlation coefficients were calculated for the assessment of relationships between continuous variables. The diagnostic performances of the variables were evaluated using receiver operating characteristic (ROC) curve analysis. P-values <0.05 were accepted as statistically significant.

Results

A total of 69 patients with CD and 60 healthy participants were included in the study. The median age of the patients with CD was 34 (range, 29–42) years, and for the healthy individuals, it was 29 (range, 26–35) years. Fifty-three (76.81%) patients with CD and 31 (51.67%) controls were male. A statistically significant difference was found regarding age and sex between the two groups (P < 0.004 and 0.005, respectively) (Table 1).

Table 1

Demographic and biochemical characteristics of participants.

	Control	Crohn’s disease	p value
	(n = 60)	(n = 69)
Age	29 (26–35)	34 (29–42)	0.004
Sex
Female	29 (48.33%)	16 (23.19%)	0.005
Male	31 (51.67%)	53 (76.81%)
CRP	0.84 (0.44–1.56)	28.00 (12.00–79.00)	<0.001
Hemoglobin	14.12 ± 1.54	12.14 ± 2.36	<0.001
RBC (x106)	4.90 ± 0.50	4.71 ± 0.72	0.087
RDW	12.6 (12.2–13.2)	14.7 (13.5–16.8)	<0.001
MPV	10.14 ± 0.80	9.51 ± 0.92	<0.001
Platelet (x103)	255.57 ± 48.86	374.62 ± 155.31	<0.001
WBC (x103)	6.69 (5.72–7.90)	9.00 (7.50–12.20)	<0.001
Neutrophils (x103)	3.56 (3.14–4.51)	6.20 (4.70–8.30)	<0.001
Lymphocyte (x103)	2.45 ± 0.76	1.89 ± 0.72	<0.001
NLR	1.57 (1.23–1.85)	3.43 (2.45–5.00)	<0.001
PLR	112.15 (82.20–136.62)	193.13 (137.50–265.33)	<0.001
NLRC4	99.43 (83.52–137.79)	71.02 (46.59–85.51)	<0.001
MCP2/CCL8	59.96 (40.22–105.59)	28.68 (20.16–46.00)	<0.001

CRP: C-reactive protein, RBC: Red blood cell, RDW: Red cell distribution width, MPV: Mean platelet volume, WBC: White blood cell, NLR: Neutrophil to Lymphocyte ratio, PLR: Platelet to lymphocyte ratio, NLRC4: Nucleotide-binding and oligomerization domain-like receptor family CARD domain-containing protein 4, MCP2/CCL8: Monocyte chemotactic protein 2/ chemokine ligand 8. Data are given as mean ± standard deviation or median (1st quartile—3rd quartile) for continuous variables according to the normality of distribution and as frequency (percentage) for categorical variables.

NLRC4 and MCP2/CCL8 levels were found to be negatively correlated with age, CRP, RDW, NLR, PLR, and positively correlated with platelet count, WBC, neutrophil count, and lymphocyte count (p<0.05) (Table 2).

Table 2

Correlation between NLRC4 and MCP2/CCL8 levels and other parameters.

	NLRC4		MCP2/CCL8
	r	p	r	p
NLRC4	-	-	0.755	<0.001
Age	-0.208	0.018	-0.275	0.002
CRP	-0.450	<0.001	-0.332	<0.001
Hemoglobin	0.250	0.004	0.053	0.550
RBC	0.108	0.224	-0.031	0.729
RDW	-0.379	<0.001	-0.188	0.033
MPV	0.073	0.413	0.069	0.434
Platelet	0.425	<0.001	0.421	<0.001
WBC	0.376	<0.001	0.384	<0.001
Neutrophils	0.373	<0.001	0.391	<0.001
Lymphocyte	0.398	<0.001	0.361	<0.001
NLR	-0.309	<0.001	-0.205	0.020
PLR	-0.270	0.002	-0.194	0.027

CRP: C-reactive protein, RBC: Red blood cell, RDW: Red cell distribution width, MPV: Mean platelet volume, WBC: White blood cell, NLR: Neutrophil to Lymphocyte ratio, PLR: Platelet to lymphocyte ratio, NLRC4: Nucleotide-binding and oligomerization domain-like receptor family CARD domain-containing protein 4, MCP2/CCL8: Monocyte chemotactic protein 2/ chemokine ligand 8.

The sites of gastrointestinal involvement of the patients were as follows: ileocolonic (n = 22, 31.88%), colonic (n = 21, 30.43%), ileocecal (n = 13, 18.84%), and ileal (n = 13, 18.84%) (Table 2). Thirty-four patients presented with inflammatory CD, 17 had fistulizing CD, and 16 patients had stricture formation. Thirty-one patients received treatment for CD (Table 3).

Table 3

Patients’ characteristics of Crohn’s disease.

Involvement
Ileal	13 (18.84%)
Ileocaecal	13 (18.84%)
Ileocolonic	22 (31.88%)
Colonic	21 (30.43%)
Column L
1	5 (7.25%)
2	30 (43.48%)
3	29 (42.03%)
4	5 (7.25%)
Column M	9 (7–11)
Type
Inflammatory	34 (49.28%)
Stricture Formation	16 (23.19%)
Fistulizing	17 (24.64%)
Stricture Formation + Fistulizing	2 (2.90%)
Treatment	31 (44.93%)

Data are given as median (1st quartile—3rd quartile) for continuous variables according to normality of distribution and as frequency (percentage) for categorical variables.

The median serum NLRC4 levels were found to be lower in patients with CD than in the healthy participants (71.02 (range, 46.59–85.51) pg/mL vs. 99.43 (range, 83.52–137.79) pg/mL) (P < 0.001). The median serum levels of MCP2/CCL8 were significantly lower in the patient group (28.68 (range, 20.16–46.0) pg/mL) compared with the control group (59.96 (range, 40.22–105.59) pg/mL) (P < 0.001). The median levels of serum CRP, RDW, WBC, neutrophils, NLR, and PLR were significantly higher in patients with CD than in the controls (all, P < 0.005). The mean hemoglobin and MPV levels were lower in patients with CD (all, P < 0.005). In addition, platelet counts were 374.62 ± 155.31 x103 /μL in the patient group and 255.57 ± 48.86 x103 /μL in the control group (P < 0.001). The mean RBC values were found similar between the two groups (P < 0.087). The participants’ biochemical characteristics are presented in Table 1.

Receiver operating characteristics (ROC) curve analysis was performed to determine the diagnostic accuracies of NLRC4 and MCP2/CCL8 for active CD (Table 4 and Fig 1). ROC curve analysis showed that <81 pg/mL NLRC4 as the cut-off point for the prediction of active CD had a sensitivity and specificity of 73.53% and 81.67%, respectively (area under the ROC curve (AUC): 0.777). The optimum cut-off point of <40 pg/L for MCP2/CCL8 had a sensitivity of 71.01% and specificity of 76.67% for diagnosing active CD, with an AUC of 0.752.

Table 4

Measurements of performance to determine active Crohn’s disease.

	NLRC4	MCP2/CCL8
Cut-off	<81	<40
Sensitivity	73.53%	71.01%
Specificity	81.67%	76.67%
Accuracy	77.34%	73.64%
Positive predictive value	81.97%	77.78%
Negative predictive value	73.13%	69.70%
AUC (95.0% CI)	0.777 (0.696–0.859)	0.752 (0.667–0.836)
p value	<0.001	<0.001

NLRC4: Nucleotide-binding and oligomerization domain-like receptor family CARD domain-containing protein 4, MCP2/CCL8: Monocyte chemotactic protein 2/ chemokine ligand 8, AUC: Area Under ROC Curve, CI: Confidence Intervals.

Fig 1

ROC analysis of the NLRC4 and MCP2/CCL8 to determine active Crohn’s disease.

ROC: Receiver operating characteristics, NLRC4: Nucleotide-binding and oligomerization domain-like receptor family CARD domain-containing protein 4, MCP2: Monocyte chemotactic protein 2.

Discussion

The study is the first to evaluate serum MCP2/CCL8 and NLRC4 levels in patients with active CD. We demonstrated significantly lower serum NLRC4 levels among patients with active CD than in healthy individuals. We also demonstrated that serum MCP2/CCL8 levels were found to be significantly lower in patients with active CD compared with healthy subjects. Cut-off values of <81 pg/mL for NLRC4 and <40 pg/mL for MCP2/CCL8 showed high sensitivity and specificity in identifying active CD.

CD is characterized by malfunction of immune-regulatory mechanisms and signaling pathways with disturbed intestinal mucosal homeostasis and increased, uncontrolled activation of mucosal effector immune cells, leading to the abnormal secretion of numerous pro- and anti-inflammatory mediators that enhance the inflammatory processes [16]. However, the cellular and molecular mechanisms that trigger these processes remain largely unclear. Chemokines are inducible, immune-regulatory proteins that are required for overall systemic inflammation and homeostasis of immune functions, involving the recruitment of immune cells, as well as the adhesion and migration of leukocytes at the site of inflammation [6]. Both experimental studies and clinical investigations have reported the role of numerous chemokines in the pathogenesis of inflammatory bowel disease (IBD). However, serum levels of chemokines have been poorly investigated. Grimm et al. demonstrated increased expression and production of monocyte chemoattractant protein (MCP-1) in inflamed intestinal mucosa, suggesting the role for MCP-1 in monocyte activation and attraction to the mucosal lesions of IBD [17]. In an experimental mice model, it was shown that the absence of MCP-1 was associated with a prominent decrease in the severity of colitis and mortality [18]. In 42 patients with IBD and 10 healthy individuals, Singh et al. showed that serum levels of macrophage migration factor (MIF), CCL21, CCL23, CCL25, CXCL5, CXCL10, CXCL11, CXCL13, MCP-1 were increased in patients with IBD compared with healthy subjects [6]. Cibor et al. revealed that serum MCP-1 levels did not alter between patients with varying activity of IBD in 56 patients with ulcerative colitis (UC), 66 with CD, and 40 healthy subjects [19].

MCP2/CCL8 has been shown as an agonist of C-C chemokine receptor type 2 (CCR2), CCR3 and CCR5 and is expressed in inflamed tissues by monocyte/macrophages following paracrine stimulation from T cell lymphocytes via pro-inflammatory cytokines, or through innate mechanisms by interactions with bacterial, viral and fungal pathogens [20]. However, the cellular origin, expression mechanism, and biologic role of MCP2/CCL8 under physiologic or pathologic conditions are not fully elucidated [7]. Gong et al. found that CCL8 was a potent inhibitor of CD4/CCR-5, and mediated HIV-1 entry and replication [21]. Hori et al. demonstrated in a mouse model that serum CCL8 levels were closely correlated to graft versus host disease (GVHD) severity, suggesting that it could be used as a specific serum marker for the early and accurate diagnosis of GVHD [22]. In an experimental mouse study, Lu et al. demonstrated that colonic inflammation could induce increased expression of CCL8 and its receptor CCR5 in the neurons of the spinal column by activating the extracellular signal-regulated kinase pathway [20]. Asano et al. showed that intestinal CD169+ macrophage-derived CCL8 functioned as a stimulant for the breakdown of barrier defense in experimentally induced colitis in mice, and anti-CCL8 neutralizing antibody was a promising target for the suppression of mucosal damage and clinical symptoms of experimentally induced colitis. [7]. Banks et al. demonstrated that the expression of MCP-2 was upregulated in patients with IBD and correlated with disease activity in an immunohistochemical study of colonic mucosal biopsy specimens [23]. We found decreased serum levels of MCP2/CCL8 in patients with active CD as compared with healthy individuals. Our results indicate that MCP2/CCL8 is involved in the pathogenesis of CD. A decrease in MCP2/CCL8 levels may affect the development and progression of local intestinal inflammation and tissue destruction in patients with CD through cellular and molecular interactions between epithelial, immune, and inflammatory cells. Our results also suggest that MCP2/CCL8 could be used as diagnostic tool and therapeutic target for CD. It also suggested that MCP2/CCL8 may have a role in disease activity because our study group comprised patients with active CD.

Inflammasomes are multimolecular complexes that initiate innate immune responses and assemble in response to endogenous and pathogen stimuli to maintain cellular integrity and control host-microbiota interactions [8]. NLRC4 activates caspase-1, which induces the maturation and secretion of inflammatory cytokines, IL-1β, IL-18, and gasdermin D to recruit phagocytic cells, epithelial repair, angiogenesis, and the regulation of chemokines and cytokines at the site of damage [24]. NLCR4 is also involved in host intestinal defense through the discrimination of commensals and harmful intestinal pathogens [25]. Franchi et al. revealed reduced neutrophil recruitment in the Salmonella-infected NLRC4-decifient or IL-1-deficient mice compared with wild-type mice, resulting in limited intestinal inflammation and an inability to control intestinal infection [25]. Studies have reported the role of inflammasomes in the pathogenesis of IBD. Schoultz et al. demonstrated that Swedish men who had the NLRP3 polymorphism exhibited an increased risk of developing CD in 498 patients with CD and 742 controls [26]. In contrast, Lewis et al. revealed no genetic association between NLRP3 and CD in a large panel in the United Kingdom with 1298 patients with CD and 1244 healthy individuals [27]. Chen et al. showed increased serum NLRP3 levels in patients with severe UC compared with a mild/moderate group [28]. Romberg et al. demonstrated in a family that the NLRC4 mutation led to periodic fever, neonatal-onset enterocolitis, fatal or near-fatal attacks of autoinflammation, causing the production of a constitutive IL-1 family cytokine and pyroptotic cell death in macrophages [13]. Canna et al. showed that the heterozygous mutation in NLRC4 caused persistent fever and enterocolitis following parainfluenza infection in a previously healthy 6-week-old patient and was successfully treated with IL-18 inhibition [29]. We showed lower serum NLCR4 levels in patients with active CD than in healthy subjects. Our result indicates that NLRC4 may contribute to the pathogenesis of CD and may have a protective effect on intestinal homeostasis and inflammation through IL-1 and IL-18 processing in patients with CD. Our result suggests that serum levels of NLRC4 may be a useful biomarker for identifying patients with active CD.

The first limitation of our study was its relatively small sample size, which was from a single center. Secondly, we determined the disease activity by CDAI, without endoscopic evaluation. Thirdly, ELISA was used to evaluate MCP2/CCL8 and NLRC4 levels, which is not the gold standard. Finally, the difference in age, gender, and medication frequency between the case group and the control group may have affected the results.

In conclusion, this is the first study to examine circulating levels of MCP2/CCL8 and NLRC4 levels in active patients with CD. We demonstrated significantly decreased serum levels of NLRC4 and MCP2/CCL8 levels in patients with active CD compared with healthy subjects. Serum NLRC4 and MCP2/CCL8 levels are involved in the pathogenesis of CD and may have a protective effect on intestinal homeostasis and inflammation and could be used as a diagnostic tool and therapeutic target for CD.

(XLS)

Click here for additional data file.

2 Sep 2021

PONE-D-21-18558

Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn’s disease

PLOS ONE

Dear Dr. Irak,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. The reviewer recommends minor revisions.

Please submit your revised manuscript by Oct 15 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

David M. Ojcius

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure:

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

4. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

5. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors studied – for the first time - the serum levels of MCP2/CCL8 and NLRC4 in active CD and found significant differences compared with the control group. This finding could be useful in clinical practice, both in diagnostic and therapy of CD.

I have some suggestions for the authors:

1. The Montreal classification of CD (location, behavior) – has no relevance in this study.

2. Please be more precious regarding the selection of the control group; as there are significant differences regarding age and sex it would be useful to check if there are any variation of studied inflammatory markers in general population related to age and sex.

3. There are some already known inflammatory markers (CRP, RDW, WBC, neutrophils, NLR, PLR, platelets) found to be different from control group but this is not relevant in this study; it would be interesting to compare these known markers with MCP2/CCL8 and NLRC4.

4. It is well known that it is no correlation between CDAI and mucosal inflammation; maybe adding calprotectin evaluation will add additional value of the study.

5. Some items in the discussion section are not supported by the results (“This supports the role of neutrophils in regulating leukocyte activation and migration in the intestinal damage, inflammation in general, and also as an indicator of disease severity”).

6. The treatment may play a role in levels of MCP2/CCL8 and NLRC4. Although the patients had active CD only 31 had treatment. Please explain.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

12 Oct 2021

Reviewer #1: The authors studied – for the first time - the serum levels of MCP2/CCL8 and NLRC4 in active CD and found significant differences compared with the control group. This finding could be useful in clinical practice, both in diagnostic and therapy of CD.

I have some suggestions for the authors:

1. The Montreal classification of CD (location, behavior) – has no relevance in this study.

The data of the study is presented in an additional excel file.

2. Please be more precious regarding the selection of the control group; as there are significant differences regarding age and sex it would be useful to check if there are any variation of studied inflammatory markers in general population related to age and sex.

As far as we examined, inflammatory marker variation between different gender and age groups has not been clearly demonstrated. Even so, the difference in age and gender frequency between the case group and the control group in our study may have affected the results. We mentioned this situation in the limitations section.

3. There are some already known inflammatory markers (CRP, RDW, WBC, neutrophils, NLR, PLR, platelets) found to be different from control group but this is not relevant in this study; it would be interesting to compare these known markers with MCP2/CCL8 and NLRC4.

Correlation analyses were added as suggested

4. It is well known that it is no correlation between CDAI and mucosal inflammation; maybe adding calprotectin evaluation will add additional value of the study.

Very few of the patients included in the study have calprotectin data, which is not sufficient for analysis.

5. Some items in the discussion section are not supported by the results (“This supports the role of neutrophils in regulating leukocyte activation and migration in the intestinal damage, inflammation in general, and also as an indicator of disease severity”).

The relevant part has been removed

6. The treatment may play a role in levels of MCP2/CCL8 and NLRC4. Although the patients had active CD only 31 had treatment. Please explain.

Although 31 patients received treatment, they applied with disease activation. Other patients were diagnosed with CD at the time of enrollment in the study and have not received any treatment yet. The possible effect of medication differences between the groups on the results is added to the limitations section.

Submitted filename: Response.docx

Click here for additional data file.

2 Nov 2021

Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn’s disease

PONE-D-21-18558R1

Dear Dr. Irak,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

David M. Ojcius

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: It is an interesting work that evaluates, for the first time, the role of serum levels of MCP2/CCL8 and NLRC4 in active CD.

The authors responded promptly to all comments in the first revision.

Although some problems remain insufficiently evaluated (value of markers used in inactive CD compared to the control group, correlation with endoscopic activity / fecal calprotectin) I believe that, through the quality of the study and the novelty of the approach, the paper can be published.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

8 Nov 2021

PONE-D-21-18558R1

Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn’s disease

Dear Dr. Irak:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. David M. Ojcius

Academic Editor

PLOS ONE